Studies immune cells in people with advanced chronic kidney disease
Observes immune T cells from blood samples in adults with end-stage kidney disease.
Key facts
- Who runs it
- Centre Hospitalier Régional d'Orléans
- Where
- Orléans, FranceSee the site
- Trial code
- Registry title
- Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 27 Nov 2024
- Expected to end
- Dec 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- 1 blood sample for each participant
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults to give one blood sample so researchers can study T-cell immune response in chronic kidney disease.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- The record names chronic or end-stage kidney disease as the study subject, but gives no exact stage in the criteria.
- Earlier treatment
- Cannot have taken immunosuppressive drugs such as Rituximab, Eculizumab, Tacrolimus, Ciclosporin, Cellcept or Imurel within the last 2 years.
Main reasons for not taking part
- Chronic progressive infections
- Prior organ transplantation, including bone marrow transplantation
- Immunosuppressive drugs within the last 2 years
- Under guardianship, curatorship or deprived of liberty
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Male or female ≥ 18 years
- Informed participants who did not object to participating in the study
Who cannot take part
- Prior organ transplantation (including bone marrow transplantation)
- Previous treatment with immunosuppressive agents (such as Rituximab, Eculizumab, Tacrolimus or Ciclosporin, Cellcept or Imurel) within 2 years prior to inclusion
- Chronic progressive infections
- Participant under guardianship, curatorship or deprived of liberty
- Pregnant or breastfeeding women
Where in France
- Center Hospitalier Universitaire d'OrléansOrléans, FranceContact: Manon DEKEYSER, PhDTaking people
About the trial
What the trial wants to find out
This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease.
Read full original descriptionShow less
The study population was patients with chronic kidney disease.
The 3 groups in the trial
- n°1 (ESKD)
end-stage chronic kidney disease
Treatment: 1 blood sample for each participant
- n°2 (stage 3 CKD)
stage 3 chronic kidney disease
Treatment: 1 blood sample for each participant
- n°3 (healthy donors)
healthy donors
Treatment: 1 blood sample for each participant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic End-stage Kidney Disease Patients.
- Plain-language title
- Studies immune cells in people with advanced chronic kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 June 2026